Recent Submissions

  • Item
    Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
    (Elsevier, 2018-09-29) Bousquet, J; Hellings, P.W; Agache, I; Amat, F; Annesi-Maesano, I; Ansotegui, I.J; Anto, J.M; Bachert, C; Bateman, E.D; Bedbrook, A; Bennoor, K; Bewick, M; Bindslev-Jensen, C; Bosnic-Anticevich, S; Bosse, I; Brozek, J; Brussino, L; Canonica, G.W; Cardona, V; Casale, T; Cepeda Sarabia, A.M; Chavannes, N.H; Cecchi, L; Correia de Sousa, J; Costa, E; Cruz, A.A; Czarlewski, W; De Carlo, G; De Feo, G; Demoly, P; Devillier, P; Dykewicz, M.S; El-Gamal, Y; Eller, E.E; Fonseca, J.A; Fontaine, J.F; Fokkens, W.J; Guzmán, M.A; Haahtela, T; Illario, M; Ivancevich, J.C; Just, J; Kaidashev, I; Khaitov, M; Kalayci, O; Keil, T; Klimek, L; Kowalski, M.L; Kuna, P; Kvedariene, V; Larenas-Linnemann, D; Laune, D; Le, L.T.T; Carlsen, K.L; Lourenço, O; Mahboub, B; Mair, A; Menditto, E; Milenkovic, B; Morais-Almeida, M; Mösges, R; Mullol, J; Murray, R; Naclerio, R; Namazova-Baranova, L; Novellino, E; O'Hehir, R.E; Ohta, K; Okamoto, Y; Okubo, K; Onorato, G.L; Palkonen, S; Panzner, P; Papadopoulos, N.G; Park, H.S; Paulino, E; Pawankar, R; Pfaar, O; Plavec, D; Popov, T.A; Potter, P; Prokopakis, E.P; Rottem, M; Ryan, D; Salimäki, J; Samolinski, B; Sanchez-Borges, M; Schunemann, H.J; Sheikh, A; Sisul, J.C; Rajabian-Söderlund, R; Sooronbaev, T; Stellato, C; To, T; Todo-Bom, A.M; Tomazic, P.V; Toppila-Salmi, S; Valero, A; Valiulis, A; Valovirta, E; Ventura, M.T; Wagenmann, M; Wang, D.Y; Wallace, D; Waserman, S; Wickman, M; Yorgancioglu, A; Zhang, L; Zhong, N; Zidarn, M; Zuberbier, T; Mobile Airways Sentinel Network (MASK) Study Group
    Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.
  • Item
    Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012)
    (Wiley, 2018-08-07) Olorunfemi, G; Ndlovu, N; Masukume, G; Chikandiwa, A; Pisa, P.T; Singh, E
    Cervical cancer (CC) is the leading cause of cancer death among female South Africans (SA). Improved access to reproductive health services following multi-ethnic democracy in 1994, HIV epidemic, and the initiation of CC population-based screening in early 2000s have influenced the epidemiology of CC in SA. We therefore evaluated the trends in CC age-standardised incidence (ASIR) (1994-2009) and mortality rates (ASMR) (2004-2012) using data from the South African National Cancer Registry and the Statistics South Africa, respectively. Five-year relative survival rates and average per cent change (AAPC) stratified by ethnicity and age-groups was determined. The average annual CC cases and mortalities were 4,694 (75,099 cases/16 years) and 2,789 (25,101 deaths/9 years), respectively. The ASIR was 22.1/100,000 in 1994 and 23.3/100,000 in 2009, with an average annual decline in incidence of 0.9% per annum (AAPC = -0.9%, p-value < 0.001). The ASMR decreased slightly by 0.6% per annum from 13.9/100,000 in 2004 to 13.1/100,000 in 2012 (AAPC = -0.6%, p-value < 0.001). In 2012, ASMR was 5.8-fold higher in Blacks than in Whites. The 5-year survival rates were higher in Whites and Indians/Asians (60-80%) than in Blacks and Coloureds (40-50%). The incidence rate increased (AAPC range: 1.1-3.1%, p-value < 0.001) among young women (25-34 years) from 2000 to 2009. Despite interventions, there were minimal changes in overall epidemiology of CC in SA but there were increased CC rates among young women and ethnic disparities in CC burden. A review of the CC national policy and directed CC prevention and treatment are required to positively impact the burden of CC in SA.
  • Item
    Accuracy of five plasma calibrated glucometers to screen for and diagnose gestational diabetes mellitus in a low resource clinic setting
    (Elsevier, 2019-12-08) Dickson, L.M; Buchmann, E.J; Janse van Rensburg, C; Norris, S.A
    Aims: We investigated the clinical and analytic accuracy of five plasma calibrated glucometers, the use of which is advocated by the World Health Organisation and the International Federation of Gynaecology and Obstetrics, to screen for and diagnose gestational diabetes mellitus (GDM) in low resource settings. Methods: 592 consecutive black African women underwent a 75 g oral glucose tolerance test (OGTT) at 24-28 weeks gestation at an urban South African community health clinic. Capillary glucose was measured by one of five glucometer brands, each paired with a routine laboratory hexokinase method of plasma glucose measurement. The laboratory results served as the gold standard reference test for GDM diagnosis. World Health Organisation GDM diagnostic thresholds were applied to glucometer and laboratory results. Results: Glucometer and laboratory determined GDM prevalence was 75/592 (12.7%) and 30/592 (5.1%) with an elevated fasting glucose diagnostic in 64/75 (85%) and 24/30 (80%) of cases respectively. The proportion of glucometer results fulfilling ISO 15197:2013 recommended analytic accuracy at fasting, 60, and 120 min of the OGTT was 92.4%, 49.8% and 61.5%, with Bland Altman method revealing a positive glucometer bias of 0.22 mmol/l (-0.69-1.12 mmol/l), 0.96 mmol/l (-0.65-2.56 mmol/l) and 0.73 mmol/l (-0.73-2.19 mmol/l) respectively. Only three of the glucometer brands evaluated fulfilled ISO 15197:2013 analytic accuracy requirements and this was only achieved at fasting. All glucometers tested were inaccurate at one and two hours of the OGTT. Conclusions: Not all glucometers may be suitable for GDM screening as only three were accurate compared to the reference test and then only at fasting of the OGTT. Importantly, laboratory fasting glucose was diagnostic of GDM in 80% of cases in this study population.
  • Item
    Sugar-sweetened beverage intake and relative weight gain among South African adults living in resource-poor communities: Longitudinal data from the STOP-SA study
    (Springer Nature, 2018-12-05) Okop, K J; Lambert, E V; Alaba, O; Levitt, N S; Luke, A; Dugas, L; Rvh, D; Kroff, J; Micklesfield, L K; Kolbe-Alexander, T L; Warren, S; Dugmore, H; Bobrow, K; Odunitan-Wayas, F A; Puoane, T
    Background: In the U.S., neoadjuvant chemotherapy (NAC) for nonmetastatic breast cancer (BC) is used with extensive disease and aggressive molecular subtypes. Little is known about the influence of demographic characteristics, clinical factors, and resource constraints on NAC use in Africa. Materials and methods: We studied NAC use in a cohort of women with stage I-III BC enrolled in the South African Breast Cancer and HIV Outcomes study at five hospitals. We analyzed associations between NAC receipt and sociodemographic and clinical factors, and we developed Cox regression models for predictors of time to first treatment with NAC versus surgery. Results: Of 810 patients, 505 (62.3%) received NAC. Multivariate analysis found associations between NAC use and black race (odds ratio [OR] 0.49; 95% confidence limit [CI], 0.25-0.96), younger age (OR 0.95; 95% CI, 0.92-0.97 for each year), T-stage (T4 versus T1: OR 136.29; 95% CI, 41.80-444.44), N-stage (N2 versus N0: OR 35.64; 95% CI, 16.56-76.73), and subtype (triple-negative versus luminal A: OR 5.16; 95% CI, 1.88-14.12). Sites differed in NAC use (Site D versus Site A: OR 5.73; 95% CI, 2.72-12.08; Site B versus Site A: OR 0.37; 95% CI, 0.16-0.86) and time to first treatment: Site A, 50 days to NAC versus 30 days to primary surgery (hazard ratio [HR] 1.84; 95% CI, 1.25-2.71); Site D, 101 days to NAC versus 126 days to primary surgery (HR 0.49; 95% CI, 0.27-0.89). Conclusion: NAC use for BC at these South African hospitals was associated with both tumor characteristics and heterogenous resource constraints.
  • Publication
    The direct medical cost of type 2 diabetes mellitus in South Africa: A cost of illness study
    (Taylor & Francis Group, 2019-07-08) Erzse, A; Stacey, N; Chola, L; Tugendhaft, A; Freeman, M; Hofman, K; Agnes Erzse, Nicholas Stacey, Lumbwe Chola, Aviva Tugendhaft & Karen Hofman: SAMRC/Wits Centre for Health Economics and Decision Science - PRICELESS SA
    Background: Type 2 diabetes mellitus (T2DM) is known to require continuous clinical care and management that consumes significant health-care resources. These costs are not well understood, particularly in low- and middle-income countries. Objective: The aim of this study was to estimate the direct medical costs associated with T2DM in the South African public health sector and to project an estimate of the future direct costs of T2DM by 2030. Methods: A cost of illness study was conducted to estimate the direct medical costs of T2DM in South Africa in 2018 and to make projections for potential costs in 2030. Costs were estimated for diagnosis and management of T2DM, and related complications. Analyses were implemented in Microsoft Excel, with sensitivity analysis conducted on particular parameters. Results: In 2018, public sector costs of diagnosed T2DM patients were approximately ZAR 2.7 bn and ZAR 21.8 bn if both diagnosed and undiagnosed patients are considered. In real terms, the 2030 cost of all T2DM cases is estimated to be ZAR 35.1 bn. Approximately 51% of these estimated costs for 2030 are attributable to the management of T2DM, and 49% are attributable to complications. Conclusion: T2DM imposes a significant financial burden on the public healthcare system in South Africa. Treatment of all prevalent cases would incur a cost equivalent to approximately 12% of the total national health budget in 2018. With rising prevalence, direct costs will grow if current care regimes are maintained and case-finding improved. Increased financial resources are necessary in order to deliver effective services to people with T2DM.

Communities in SAMRC InfoSpace

Select a community to browse its collections.